Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 8 of 23

  1. Mixed-Amphetamine Salts- Extended Release (MAS-ER)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  2. Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    3 trials

  3. Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule active

    2 trials

  4. Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    2 trials

  5. Modafinil 0 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  6. Modafinil 200mg

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 2 small molecule terminated

    1 trial

  7. Monitoring and Feedback Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  8. Mood Management Phone Counseling for Smoking Cessation

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    phase 2 other completed

    1 trial

  9. Motivational enhancement therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Abuse

    phase 2 other completed

    1 trial

  10. Motivational interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Adherence

    phase 2 other active

    1 trial

  11. Moxifloxacin (M)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  12. Multimedia WORTH

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  13. N Acetyl Cysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Gambling

    phase 2 small molecule completed

    1 trial

  14. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  15. N-acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  16. N-acetylcysteine (NAC)

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  17. NAP (Naptumomab estafenatox)

    BRIGHT MINDS BIOSCIENCES INC.

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  18. Nab paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  19. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial

  20. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 2 small molecule terminated

    1 trial

  21. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Stable Opioid Dependence

    phase 2 small molecule completed

    1 trial

  22. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

  23. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    3 trials

  24. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule completed

    3 trials

  25. Naltrexone (drug)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  26. Naltrexone hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 2 small molecule active

    1 trial

  27. Navigating my Journey program

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  28. Nefazodone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  29. Nepicastat

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  30. NicVAX

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 mab completed

    1 trial

  31. NicVAX conjugate vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 mab completed

    1 trial

  32. Nicotine 0 mg/mL

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine

    phase 2 small molecule completed

    1 trial

  33. Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    2 trials

  34. Nicotine gum and lozenge

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  35. Nicotine replacement

    BRIGHT MINDS BIOSCIENCES INC.

    Cardiovascular Disease

    phase 2 small molecule completed

    1 trial

  36. Nimodipine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  37. Nitrous oxide

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  38. OND-PR002 and MPh-IR

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  39. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  40. Omnitram Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  41. Ondansetron

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 small molecule completed

    1 trial

  42. Opioid-Related Disorders

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    3 trials

  43. Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  44. Oshadi Icp

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Insulin-Dependent, 1

    phase 2 small molecule completed

    1 trial

  45. Oxytocin

    BRIGHT MINDS BIOSCIENCES INC.

    Social Cognition

    phase 2 small molecule completed

    1 trial

  46. PA-824

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    3 trials

  47. PA-824

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 2 small molecule completed

    2 trials

  48. PF-04457845

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.